echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Can everolimus combined with aromatase inhibitors be used as a maintenance treatment for metastatic breast cancer?

    Eur J Cancer: Can everolimus combined with aromatase inhibitors be used as a maintenance treatment for metastatic breast cancer?

    • Last Update: 2021-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Although endocrine therapy is the main treatment for hormone receptor positive (HR+)/HER2-metastatic breast cancer , patients who are at risk of visceral crisis or have insufficient sensitivity to endocrine therapy require first-line chemotherapy
    .


    Hormonal maintenance therapy is usually given when chemotherapy is stopped


    Breast cancer

    Recruited patients with ER+/HER2-metastatic breast cancer who had achieved partial remission or complete remission after first-line chemotherapy and were randomly divided into two groups and received everolimus combined with AI (exemestane or letrozole).
    Or Anastrozole) or AI therapy alone
    .


    The primary endpoint is progression-free survival (PFS)


    PFS and OS of the two groups

    PFS and OS of the two groups

    In total, 110 patients were randomly divided into two groups: 52 in the everolimus + AI group and 58 in the AI ​​group
    .


    The median PFS of the everolimus+AI group and the AI ​​group were 11.


    The median PFS of everolimus + AI group and AI group were 11.


    Everolimus combined with AI did not significantly improve the prognosis of patients with metastatic breast cancer after first-line chemotherapy compared with AI alone


    Original source:

    Guarneri Valentina,Giorgi Carlo Alberto,Cinieri Saverio et al.


    Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.